The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone developmentDavide Rossi, Gianluca Gaïdano|The Journal of Experimental Medicine|2012Cited by 378
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Antonio Palumbo, Alessandra Larocca et al.|Blood|2011Cited by 268
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210